title: MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism.
abstract: BACKGROUND
  MicroRNAs (miRNAs) play important roles in many biological processes, including cancer development. Among those miRNAs, miR-143 shows tumor-suppressive activity in some human cancers. However, the function and mechanism of miR-143 in lung cancer cells remains unknown. Here we explored the role of miR-143 in lung cancer.
  
  
  RESULTS
  According to qRT-PCR, we found that miR-143 was notably down-regulated in 19 NSCLC tissues and 5 cell lines. In vitro experiments showed us that miR-143 could significantly suppress the migration and invasion of NSCLC cell lines while it had no effects on the growth of NSCLC cell lines, and in vivo metastasis assay showed the same results. Finally, we found that the mechanism of miR-143 inhibiting the migration and invasion of NSCLC might be through targeting CD44v3.
  
  
  CONCLUSIONS
  The up-regulated miR-143 in lung cancer could significantly inhibit cell migration and invasion, and this might work through targeting CD44v3, which was newly identified by us.
authors.affiliation: State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
authors.forename: Qingping
authors.initials: Q
authors.lastname: Ma
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Jiang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Pu
authors.forename: Xuechao
authors.initials: X
authors.lastname: Zhang
authors.forename: Weihan
authors.initials: W
authors.lastname: Yang
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Sujuan
authors.initials: S
authors.lastname: Ye
authors.forename: Shifei
authors.initials: S
authors.lastname: Wu
authors.forename: Guoxing
authors.initials: G
authors.lastname: Zhong
authors.forename: Jiang
authors.initials: J
authors.lastname: Ren
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Lunxu
authors.initials: L
authors.lastname: Liu
authors.forename: Wen
authors.initials: W
authors.lastname: Zhu
mesh_terms: D001483:Base Sequence; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D002460:Cell Line; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D015536:Down-Regulation; D055786:Gene Knockout Techniques; D006801:Humans; D018960:Hyaluronan Receptors / Q000187:drug effects*; D008175:Lung Neoplasms / Q000235:genetics*; D035683:MicroRNAs / Q000502:physiology*; D009361:Neoplasm Invasiveness / Q000503:physiopathology*; D014162:Transfection
chemical_list: C121450:CD44V3,8-10; D018960:Hyaluronan Receptors; C542359:MIRN143 microRNA, human; D035683:MicroRNAs
keywords: CD44v3.; NSCLC; invasion; miR-143; microRNA (miRNA); migration
references.citation: Curr Opin Pharmacol. 2010 Oct;10(5):543-50
references.pmid: 20541466
references.citation: Cancer Gene Ther. 2010 Jun;17(6):398-408
references.pmid: 20094072
references.citation: Cancer Cell. 2006 Mar;9(3):189-98
references.pmid: 16530703
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Mol Cell Biochem. 2011 Apr;350(1-2):207-13
references.pmid: 21197560
references.citation: Cancer Res. 2006 Nov 1;66(21):10233-7
references.pmid: 17079438
references.citation: Cancer Lett. 2011 Aug 28;307(2):211-20
references.pmid: 21550168
references.citation: Zhongguo Fei Ai Za Zhi. 2003 Dec 20;6(6):480-3
references.pmid: 21310136
references.citation: Oncogene. 2013 Jan 24;32(4):491-501
references.pmid: 22370644
references.citation: Br J Cancer. 2013 Jan 15;108(1):149-54
references.pmid: 23321517
references.citation: J Biol Chem. 2012 Apr 6;287(15):11769-77
references.pmid: 22354972
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):91-112
references.pmid: 21303969
references.citation: Cancer Res. 2009 Jul 1;69(13):5553-9
references.pmid: 19549910
references.citation: Circ Res. 2012 Feb 3;110(3):496-507
references.pmid: 22302756
references.citation: Blood. 2003 Aug 15;102(4):1169-77
references.pmid: 12714503
references.citation: Cancer Biol Ther. 2006 Sep;5(9):1163-8
references.pmid: 16855392
references.citation: Nat Rev Cancer. 2006 Jun;6(6):449-58
references.pmid: 16723991
references.citation: Biomed Pharmacother. 2010 Jul;64(6):399-408
references.pmid: 20363096
references.citation: Oncogene. 2006 Oct 9;25(46):6163-9
references.pmid: 17028595
references.citation: Asian Pac J Cancer Prev. 2011;12(4):929-33
references.pmid: 21790228
references.citation: N Engl J Med. 2005 Oct 27;353(17):1768-71
references.pmid: 16251533
references.citation: PLoS One. 2009 Oct 26;4(10):e7542
references.pmid: 19855844
references.citation: Oncogene. 2009 Mar 12;28(10):1385-92
references.pmid: 19137007
references.citation: Genes Dev. 2006 Mar 1;20(5):515-24
references.pmid: 16510870
references.citation: EMBO Mol Med. 2012 Mar;4(3):143-59
references.pmid: 22351564
references.citation: Nat Rev Cancer. 2011 Apr;11(4):254-67
references.pmid: 21390059
references.citation: Leuk Res. 2009 Nov;33(11):1530-8
references.pmid: 19464056
references.citation: PLoS One. 2008 Jul 02;3(7):e2557
references.pmid: 18596939
references.citation: Hum Pathol. 1997 Jul;28(7):809-14
references.pmid: 9224749
references.citation: Oncology. 2009;77(1):12-21
references.pmid: 19439999
references.citation: PLoS One. 2011;6(5):e20341
references.pmid: 21647377
references.citation: Mol Ther. 2011 Jun;19(6):1123-30
references.pmid: 21427707
references.citation: Virchows Arch. 2001 Nov;439(5):628-35
references.pmid: 11764382
references.citation: Biochem Biophys Res Commun. 2009 Oct 23;388(3):483-9
references.pmid: 19654003
references.citation: Pathol Int. 2012 Dec;62(12):792-801
references.pmid: 23252868
references.citation: Int J Mol Med. 2009 Nov;24(5):677-83
references.pmid: 19787202
references.citation: Mol Cancer. 2012 Apr 25;11:23
references.pmid: 22533346
references.citation: Cancer Genet Cytogenet. 2010 Jul 15;200(2):127-33
references.pmid: 20620595
references.citation: Mol Cancer Ther. 2011 Aug;10(8):1470-80
references.pmid: 21622730